Filament Health Corp.
(FH) (
N.FH,
OTCQB: FLHLF,
Forum) – a clinical-stage natural psychedelic drug development company – has announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds.
Filament's latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.
Ryan Moss, Chief Science Officer at Filament Health, commented:
"Adding a fourth patent to our portfolio demonstrates the calibre of Filament's intellectual property strategy and drug development platform. Our ability to transform valuable natural substances into IP-protected pharmaceutical-grade drug candidates sets us apart as industry leaders."
Fully story
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: Filament Health Corp. is a client of Stockhouse Publishing.